Preview Mode Links will not work in preview mode

Journal of Clinical Oncology recognizes that readers do not always have time to review an article in depth, and yet they still wish to understand how the results will influence their clinical practice or research. To address this need, we offer podcasts that will enhance the readership experience by presenting the key results of high-profile publications in a convenient audio format. Our podcasts are designed to place selected articles into a clinically useful perspective that is easy to listen to in the office or while on the road.

Life is busy, and it’s hard to get it all done during business hours! Journal of Clinical Oncology recognizes that you do not always have time to review an article in depth, and yet you wish to understand how the results will influence your clinical practice or research. JCO After Hours is a podcast intended to enhance the readership experience by presenting key results of high-profile publications in a convenient audio format, placing selected articles into a clinically useful perspective that you can listen to in the office or on the road.

  1. All Episodes
  2. 2014
  3. 03

Risk-Reducing Oophorectomy in Women with BRCA1 and BRCA2 Mutations: An Opportunity to Personalize Recommendations for Cancer Prevention

Mar 31, 2014

This podcast summarizes and provides clinical conclusions of a large international study on ovarian cancer incidence and outcomes in women with BRCA1 and BRCA2 mutations.

Read More

Anti-EGFR Monoclonal Antibodies in the First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The PEAK Experience

Mar 31, 2014

In this podcast, I will discuss first-line usage of anti-EGFR therapies in metastatic colorectal cancer in the context of the PEAK trial findings with a focus on the emerging data surrounding RAS oncogene mutations in treatment selection.

Read More

Accuracy of BRCAPRO in Women with Ovarian Cancer

Mar 17, 2014

This JCO podcast provides commentary on the accompanying JCO article "Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high grade serious ovarian cancer by BRCAPRO: A multi-institution study" by Molly S Daniels, et al, and evaluates the need for BRCAPRO in patients with ovarian cancer and the benefit...

Read More

Serious Bevacizumab-Associated Gastrointestinal Toxicity

Mar 17, 2014

This podcast discusses the results of an analysis of the risk of severe gastrointestinal toxicity associated with the administration of bevacizumab to women with advanced ovarian cancer.

Read More

The Efficacy of Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer Patients and Its Effects On Patient-Reported Outcomes

Mar 17, 2014

Observations from the AURELIA trial evaluating bevacizumab combined with chemotherapy in platinum resistant recurrent ovarian cancer patients and results from Patient-Reported Outcomes.

Read More